- Home
- AXR vs TCRX Comparison
AXR vs TCRX Comparison
Compare AXR & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXR
- TCRX
- Stock Information
- Founded
- AXR 1961
- TCRX 2018
- Country
- AXR United States
- TCRX United States
- Employees
- AXR N/A
- TCRX N/A
- Industry
- AXR Homebuilding
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- AXR Real Estate
- TCRX Health Care
- Exchange
- AXR Nasdaq
- TCRX Nasdaq
- Market Cap
- AXR 120.0M
- TCRX 100.7M
- IPO Year
- AXR N/A
- TCRX 2021
- Fundamental
- Price
- AXR $21.60
- TCRX $1.44
- Analyst Decision
- AXR
- TCRX Strong Buy
- Analyst Count
- AXR 0
- TCRX 6
- Target Price
- AXR N/A
- TCRX $9.50
- AVG Volume (30 Days)
- AXR 18.0K
- TCRX 482.2K
- Earning Date
- AXR 07-22-2025
- TCRX 08-11-2025
- Dividend Yield
- AXR N/A
- TCRX N/A
- EPS Growth
- AXR 472.07
- TCRX N/A
- EPS
- AXR 2.41
- TCRX N/A
- Revenue
- AXR $58,052,000.00
- TCRX $4,421,000.00
- Revenue This Year
- AXR $120,108.69
- TCRX $159.20
- Revenue Next Year
- AXR $8.16
- TCRX N/A
- P/E Ratio
- AXR $8.93
- TCRX N/A
- Revenue Growth
- AXR 30.35
- TCRX N/A
- 52 Week Low
- AXR $16.94
- TCRX $1.02
- 52 Week High
- AXR $39.68
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- AXR 51.49
- TCRX 44.26
- Support Level
- AXR $20.75
- TCRX $1.44
- Resistance Level
- AXR $22.11
- TCRX $1.61
- Average True Range (ATR)
- AXR 1.07
- TCRX 0.16
- MACD
- AXR 0.11
- TCRX -0.02
- Stochastic Oscillator
- AXR 56.79
- TCRX 10.44
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.